Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1654 placebo-controlled trial for prevention of RSV disease in healthy infants
MOH_2021-04-13_009414Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing MK-1654 with Placebo (2 arms). Started Dec 2020; status: active, not recruiting.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2021-04-13_009414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-13_009414.